lenvatinib + everolimus
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Clear Cell Renal Cell Carcinoma (nccRCC)
Conditions
Non Clear Cell Renal Cell Carcinoma (nccRCC)
Trial Timeline
Feb 20, 2017 → Nov 2, 2021
NCT ID
NCT02915783About lenvatinib + everolimus
lenvatinib + everolimus is a phase 2 stage product being developed by Eisai for Non Clear Cell Renal Cell Carcinoma (nccRCC). The current trial status is completed. This product is registered under clinical trial identifier NCT02915783. Target conditions include Non Clear Cell Renal Cell Carcinoma (nccRCC).
What happened to similar drugs?
3 of 13 similar drugs in Non Clear Cell Renal Cell Carcinoma (nccRCC) were approved
Approved (3) Terminated (1) Active (9)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03324373 | Phase 1 | Completed |
| NCT03245151 | Phase 1/2 | Completed |
| NCT03173560 | Phase 2 | Completed |
| NCT02915783 | Phase 2 | Completed |
| NCT02454478 | Phase 1 | Completed |
| NCT01136733 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non Clear Cell Renal Cell Carcinoma (nccRCC)